Patents Assigned to The Institute of Cancer Research
-
Patent number: 11441169Abstract: Methods and kits for sequencing and quantification of small RNA molecules from small quantities of starting materials, including single cells, are disclosed. The invention can be applied to, among others, preparing small RNA libraries, synthesizing cDNA from small RNAs, characterizing small RNAs from various cell types, studying cellular heterogeneity in pathological conditions, and diagnosing diseases.Type: GrantFiled: June 15, 2017Date of Patent: September 13, 2022Assignee: Ludwig Institute for Cancer Research LtdInventors: Omid R. Faridani, Rickard Sandberg
-
Publication number: 20220267781Abstract: This disclosure provides methods for enhancing antitumor cytotoxicity of immune cells by introducing to the immune cells a genetic modification that comprises overexpression of RHEB or a functional fragment thereof, overexpression of LAMP 1-RHEB or a functional fragment thereof, overexpression of CA9 or a functional fragment thereof, overexpression of NHE1 or a functional fragment thereof, or combination thereof.Type: ApplicationFiled: July 24, 2020Publication date: August 25, 2022Applicants: Ludwig Institute for Cancer Research Ltd, The Wistar InstituteInventors: Zandra Walton, Zachary Stine, Yaoyu Gong, Chi Van Dang
-
Patent number: 11419955Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: December 13, 2019Date of Patent: August 23, 2022Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 11400090Abstract: The present invention provides a medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising as an active ingredient a compound represented by formula or a pharmaceutically acceptable salt thereof, wherein the medicament is used in such a manner that: (a) said compound or salt is administered twice weekly for 3 weeks, (b) administration of said compound or salt is paused for the following 1 week, and (c) steps (a) and (b) are subsequently repeated at least once.Type: GrantFiled: May 16, 2018Date of Patent: August 2, 2022Assignees: The Institute of Cancer Research: Royal Cancer Hospital, The Royal Marsden NHS Foundation TrustInventor: Udai Banerji
-
Patent number: 11401335Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: January 15, 2020Date of Patent: August 2, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20220227872Abstract: Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.Type: ApplicationFiled: May 29, 2020Publication date: July 21, 2022Applicants: Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, Université de LausanneInventors: Steven M. Dunn, Julie K. Fierle, George Coukos
-
Patent number: 11393654Abstract: An x-ray micro-beam radiation production system is provided having: a source of accelerated electrons, an electron focusing component configured to focus the electrons provided by the source, and a target which produces x-rays when electrons impinge thereon from the source. The electron focusing component is configured to focus the electrons provided by the source such that they impinge at a focal spot having a width ? formed on a surface of the target.Type: GrantFiled: June 14, 2017Date of Patent: July 19, 2022Assignee: The Institute of Cancer Research: Royal Cancer HospitalInventors: Stefan Bartzsch, Uwe Oelfke
-
Patent number: 11389455Abstract: The disclosure generally relates to compounds, compositions, and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: December 30, 2020Date of Patent: July 19, 2022Assignee: Institute for Cancer ResearchInventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
-
Publication number: 20220218748Abstract: The presently disclosed subject matter provides cells and compositions for improved immunotherapy and methods of using such cells and compositions. It relates to cells comprising a ligand-recognizing receptor (e.g., an antigen-recognizing receptor, e.g., a chimeric antigen receptor (CAR) or a T-cell Receptor (TCR)) and an IgG-degrading enzyme or a fragment thereof. The IgG-degrading enzyme rapidly cleaves IgG. The IgG-degrading enzyme serves as a biomolecular shield against the host humoral response. The cells have increased resistance to host humoral response (e.g., an antibody-driven host humoral response), which allows for prolonged persistence of the cells, leading to enhanced activity of the cells.Type: ApplicationFiled: February 1, 2022Publication date: July 14, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: David A. Scheinberg, Leila Peraro
-
Publication number: 20220213211Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: March 11, 2022Publication date: July 7, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Publication number: 20220195064Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Patent number: 11364234Abstract: The present application relates to the treatment of nematode infections.Type: GrantFiled: September 10, 2019Date of Patent: June 21, 2022Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
-
Patent number: 11359028Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.Type: GrantFiled: May 9, 2019Date of Patent: June 14, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Dennis J. Underwood, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Marc Van Dijk
-
Publication number: 20220177961Abstract: The present invention relates to methods for haplotype determination and, in particular, haplotype determination at the whole genome level as well as targeted haplotype determination.Type: ApplicationFiled: October 18, 2021Publication date: June 9, 2022Applicant: Ludwig Institute for Cancer Research LtdInventors: Bing Ren, Siddarth Selvaraj, Jesse Dixon, Anthony Schmitt
-
Patent number: 11345755Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 24, 2020Date of Patent: May 31, 2022Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
-
Publication number: 20220152109Abstract: The application provides genetically modified cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-1. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, including but not limited to genetically engineered cells, and pharmaceutical compositions. The application further provides the use of such modified T cell receptors (TCRs) and related compositions for cancer immunotherapy (e.g., adoptive cell therapy).Type: ApplicationFiled: March 17, 2020Publication date: May 19, 2022Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: George COUKOS, Melita IRVING, Vincent ZOETE, Olivier MICHIELIN
-
Patent number: 11332756Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.Type: GrantFiled: July 5, 2017Date of Patent: May 17, 2022Assignee: Institute For Cancer ResearchInventors: Siddharth Balachandran, Roshan Thapa
-
Patent number: 11332536Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: February 7, 2020Date of Patent: May 17, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
-
Patent number: 11325915Abstract: This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.Type: GrantFiled: October 12, 2018Date of Patent: May 10, 2022Assignee: The Institute of Cancer Research: Royal Cancer HospitalInventors: Richard Marais, Caroline Springer, Dan Niculescu-Duvaz, Natalie Miller, Mohammed Aljarah, Alfonso Zambon, Leo Leung, Deborah Smithen, Michael Brown, Haoran Tang
-
Publication number: 20220135564Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.Type: ApplicationFiled: January 30, 2020Publication date: May 5, 2022Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Andrew C. Kruegel, Dalibor Sames, Jonathan A. Javitch, Susruta Majumdar